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Therapeutic and immunological interventions  
in primary biliary cholangitis: from mouse models  
to humans
Atsushi Tanaka1, Patrick S.C. Leung2, Howard A. Young3, M. Eric Gershwin2
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease 
that predominantly affects women in their fifth and sixth decades. The 
diagnostic hallmarks of PBC are detection of anti-mitochondrial antibod-
ies (AMAs) and chronic non-suppurative destructive cholangitis (CNSDC) 
of small- and medium-sized intrahepatic bile ducts in liver histological 
examination [1, 2]. A significant amount of data suggests that immuno-
logical activity against small biliary epithelial cells (BECs), found histo-
logically as portal inflammation, leads to clinical disease. In PBC, as with 
other autoimmune diseases, both genetic and environmental factors 
contribute to the development of pathology [3–8]. The first-line therapy 
of PBC is ursodeoxycholic acid (UDCA), although obeticholic acid (OCA) 
has been approved recently for patients with an incomplete response 
to UDCA [9–11]. Unfortunately, unlike other autoimmune diseases, no 
successful clinical trials of biologics have been conducted, and the mech-
anisms of action of UDCA and OCA are not fully understood [12–16].
The clinical phenotype and the natural history of PBC vary between pa-
tients and can have other overlapping autoimmune diseases [12, 17–19]. 
For example, some patients may have mild elevation of liver enzyme levels 
and remain asymptomatic for life. By contrast, other patients can develop 
signs of liver failure and rapidly decompensate despite therapy, requiring 
liver transplantation. A presumption is that these differences are due to 
genetic and environmental factors, both contributing to the development 
of PBC to various degrees in each patient [4, 7, 20]. Although multiple ge-
nome-wide association studies (GWASs) have been reported differences 
in several genes [21–24], their clinical implications and relevance remain 
elusive [25]. In fact, in PBC, in autoimmune diseases, including PBC, the 
results of GWASs have been disappointing, and efforts have been made 
recently for both deep sequencing and study of epigenetic events [26–30]. 
To understand the importance of developing a useful mouse model, other 
aspects of PBC such as spectra of disease and gender dominance should 
be considered [18, 31].
Toward solving the etiological mystery
Most autoimmune diseases, including PBC, have a strong sex bias to-
wards women [32, 33]. Male and female immune responses differ and 
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are affected by sex hormones, X-linked genes, and 
sex-specific microbiota [34–38]. Despite extensive 
studies with clinical samples and animal models 
of PBC, no demonstrated physiological mecha-
nisms account for the strong female predomi-
nance in PBC [32, 39–48]. Epidemiological studies 
on PBC show that frequent exposure to environ-
mental chemicals such as nail polish, chemicals in 
tobacco smoke, and hormone replacement thera-
pies are significantly associated with an increased 
risk of PBC [7]. Other PBC risk factors include 
recurrent urinary tract infections and increased 
prevalence of reproductive complications [49, 50]. 
These risk factors may work synergistically in ac-
celerating loss of tolerance. One theory proposes 
that haploinsufficiency for specific X-linked genes 
leads to female susceptibility to PBC and suggests 
that enhanced monosomy X in the peripheral lym-
phocytes of affected women plays a  role in the 
induction of PBC [51, 52]. However, how these 
genetic and environmental factors interact with 
the immune system to elicit autoimmunity in PBC 
remains unclear [53].
Newly diagnosed PBC patients are often past 
their initial stages and present with elevated 
cholestatic enzymes, AMA positivity, and dense 
aggregation of lymphocytes in the liver. Investi-
gation of these patients for very early events of 
PBC is therefore inappropriate, and animal mod-
els that reflect many of the important aspects of 
the disease are much needed. The animal model 
should have the same physiological mechanisms 
that are observed in human PBC, such as female 
predominance; chronic cholestasis; AMA produc-
tion; histological features, including lymphocyte 
infiltration into the liver; and bile duct immune 
involvement. 
Efforts to establish mouse models of PBC
Several groups including, our own, have estab-
lished mouse models of PBC in a spontaneous or 
induced manner (Table I). These mice share some 
of the important clinical phenotypes of PBC, in-
cluding portal lymphocytic infiltration, presence of 
AMA against mitochondrial antigens, and chronic 
cholestasis.
Spontaneous murine models
The NOD.c3c4 mice, which have multiple B6- 
and B10-derived insulin-dependent diabetes (Idd)- 
resistant alleles on chromosomes 3 and 4, respec-
tively, of the non-obese diabetic (NOD) mice. NOD.
c3c4 mice were demonstrated to be protected 
from autoimmune diabetes and spontaneously de-
velop lymphocytic peribiliary infiltrates and AMA 
positivity [54, 55]. AMAs were detectable in 60% 
(3/5) and 57% (4/7) of mice at 9–10 weeks and 
14–20 weeks of age, respectively, and were direct-
ed against the inner lipoyl domain of PDC-E2, the 
same mitochondrial autoantigens as recognized 
in human PBC [54]. Moreover, it is noteworthy that 
AMA detection was observed in female mice, indi-
cating female predominance like in human PBC. 
However, pathological examination of the liver 
revealed biliary polycystic diseases in both intra-
biliary and extrabiliary ducts, and little evidence of 
CNSDC. The expression levels of anti-PDC-E2 anti-
bodies declined as the mice got older. Chronic bio-
chemical cholestasis was not observed. Neverthe-
less, NOD.c3c4 mice clearly indicated that genetic 
manipulation in a susceptible strain could produce 
AMA with identical antigenicity as human PBC for 
the first time, supporting the importance of genet-
ic contribution to PBC.
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The dominant-negative TGF-b receptor II 
(dnTGFbRII) mice, studied intensively by our 
group, also mimicks phenotypes of human PBC 
[56]. These mice are transgenic for the direct-
ed expression of a  dominantly negative form 
of TGF-b receptor type II, under the direction of 
the CD4 promoter. Thus, TGF-b signaling is not 
completely abolished and dnTGFbRII mice can 
survive as do non-transgenic mice. DnTGFbRII 
mice spontaneously produce AMAs directed to 
the same mitochondrial autoantigens as in hu-
man PBC, namely PDC-E2, BCOADC-E2, and OG-
DC-E2. By weeks 22–24, 100%, 95%, and 68% of 
the mice sera reacted with PDC-E2, OGDC, and 
BCOADC, respectively. Lymphocytic liver infiltra-
tion with periportal inflammation is analogous 
to the histological profile of human PBC (Fig- 
ure 1). In addition, the serum cytokine profile of 
affected mice mimics data in human PBC. DnT-
GFbRII mice, although lacking female predomi-
nance, demonstrate the role of TGF-b pathways 
in the immunopathogenesis of PBC and served 
as a model for investigating the efficacy of B-cell 
depletion therapy for PBC [57].
The third spontaneous mouse model is IL-2Ra–/– 
mice, lacking IL-2R that is crucial for differentiation 
of regulatory T cells (Tregs) and eventually reduc-
tion in Tregs [58]. We reported the case of a 5-year-
old boy with IL-2a deficiency who developed liver 
dysfunction with serological expression of PBC, 
and documented paucity in the frequency and 
absolute numbers of circulating CD4+CD25high nat-
ural Tregs in patients with PBC and their first-de-
gree relatives [59]. These observations prompted 
us to examine whether IL-2Ra–/– mice would serve 
as PBC model mice. The results were striking be-
cause the mice developed portal inflammation, 
biliary ductular damage, and a Th1 cytokine bias 
in sera, resembling human PBC. In addition, AMAs 
were detectable in all IL-2Ra–/– mice and target-
ed to the inner lipoyl domain of PDC-E2. Howev-
er, female predominance was not observed in the 
IL-2Ra–/– mice. Furthermore, absence of granulo-
mas, short life span, and presence of clinical mani-
festations such as anemia and inflammatory bow-
el diseases made the IL-2Ra–/– mice less attractive 
as a PBC model mice.
The fourth spontaneous model is the Ae2a,b–/– 
mice. AE2 is an Cl–/HCO3
– anion exchanger 2 which 
is involved in intracellular pH regulation and 
trans-epithelial acid-base transport. In 2008, Salas 
et al. reported that Ae2a,b–/– mice develop elevat-
ed levels of IL-12p70 and IFN-γ and increased 
numbers of CD8+ T cells. Interestingly, AMA and 
increased levels of IgM, IgG and alkaline phospha-
tase were also observed in Ae2a, b–/– mice. Histo-
logically, 30% of Ae2a,b–/– mice showed infiltration 
of CD4+ and CD8+ T cells in the portal areas and 
around the damaged bile duct with slight fibrosis 
around areas of bile duct obstruction [60]. 
The mechanism of this model has been ex-
plained by a  change in biliary epithelial cell ho-
meostasis due to AE2 deficiency, which increases 
intracellular pH and promotes the proliferation, 
differentiation and activity of lymphocytes, lead-
ing to an increase in the targeting sensitivity of 
CD8+ T cells, leading to biliary pathology. Although 
Ae2a,b–/–  mice  develop hepatobiliary and immu-
nological features resembling human PBC, the 
large variations in liver pathology, lack of female 
predominance and difficulties in breeding made 
Ae2a,b–/– mice limit its applications for preclinical 
studies.
Induced murine models
The three above-mentioned mice sponta-
neously developed serological and immuno-
pathological features that mimic human PBC 
after genetic manipulation (Table I), clearly indi-
cating the importance of genetics in the develop-
ment of the disease. Meanwhile, robust evidence 
supports the crucial contribution of environmen-
tal factors; in this regard, stimulation of geneti-
cally susceptible mice with environmental factors 
would be another attractive approach for break-
ing immunological tolerance against PDC-E2. To 
establish these “induced” mice model, we have 
studied chemical xenobiotics as potential envi-
ronmental factors, particularly and hypothesized 
that xenobiotic modification of native PDC-E2 
Figure 1. Histological features of the liver in dnTGFbRII mice at 24–28 weeks. Different degrees of lymphocytic 
infiltrations (red arrows) surrounding the small bile ducts, within the portal tracts (hematoxylin-eosin staining) [56]
A B C
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could elicit autoimmune response to PDC-E2 and 
break tolerance.
Based on a detailed, quantitative structure-ac-
tivity relationship analysis with 107 potential xe-
nobiotic mimics coupled to the lysine residue of 
the immunodominant 15-amino acid peptide of 
the PDC-E2 inner lipoyl domain, we found that PBC 
sera were more reactive to a number of xenobiotics 
modified PDC-E2 peptide than to the native lipoy-
lated peptide. Among them, 2-Octynoic acid (2-OA) 
was unique in both its quantitative structure-activ-
ity relationship analysis and reactivity [20]. 2-OA is 
a xenobiotic chemical that is widely used as a cos-
metic ingredient and for seasoning foods. Thus, we 
immunized C57BL/6 mice with 2-OA coupled to 
bovine serum albumin (BSA; Figure 2) and demon-
strated that anti-PDC-E2 antibodies were seropos-
itive as early as 4 weeks after immunization (Fig- 
ure 3), indicating tolerance breakdown against 
PDC-E2 with xenobiotic immunization. In addition, 
these mice have shown portal infiltration of CD4+ 
and CD8+ T cells and granulomas, and elevation of 
TNF-a and IFN-γ expression levels [61]. Therefore, 
2-OA-BSA-immunized mice provides a  suitable 
model for investigating immunopathogenesis in 
the early stage of PBC and for testing the thera-
peutic efficacy of new compounds.
To further investigate potential roles of cyto-
kine pathways, we systemically constructed sev-
eral unique gene-deleted mice, including mice 
with IL-12p40, IL-12p35, IFN-γ, IL-23p19, IL-17A, 
IL-17F, and IL-22 deletions. Then, we immunized 
these mice with 2-OA-BSA and followed their nat-
ural history [62]. The results are summarized as 
follows: (1) both IL-12/T helper type 1 (Th1) and 
IL-23/Th17 were involved in autoimmune chol-
angitis, (2) the IL-12/Th1 signaling pathway elic-
ited pathology, and (3) IFN-γ deletion prevented 
autoimmune cholangitis (Figure 4). Furthermore, 
2-OA-BSA mice were also studied for the potential 
efficacy of CTLA-4-based therapy on cholangitis by 
using CTLA4-Ig [63].
In summary, these model mice develop clinical 
and immunological characteristics as human PBC, 
including cholestasis, AMA positivity, and portal 
inflammation. However, female predominance, an 
important feature of PBC and other autoimmune 
diseases, was not manifested in most of the mice 
except for NOD.c3c4 mice. A  mouse model with 
immunological characteristics of PBC and female 
predominance will more closely reflect the human 
disease. Therefore, we focused on IFN-γ based 
on extensive efforts of Dr. Howard Young et al. 
on a interesting IFN-γ designer mouse, described 
below, and also in part on numerous studies that 
reported that IFN-γ plays an essential role in the 
development and severity of female-dominant au-
toimmune diseases [34].
IFN-γ as a key molecule of PBC
There are several lines of evidence that IFN-γ 
is involved in the pathogenesis of autoimmune 
cholangitis: (i) Immunohistochemistry staining in 
PBC livers demonstrates that, IL-12/Th1 cytokines 
are dominant in the inflamed portal area with 
IFN-γ-positive monocular cells surrounding de-
generated cholangiocytes in the early stage of 
disease, whereas the Th1/Th17 balance is skewed 
toward IL-23/Th17 in advanced stages of PBC [64]. 
(ii) As described previously, liver histology in a xe-
nobiotic induced model demonstrated that both 
IL-12/Th1 and IL-23/Th17 are involved in cholan-
gitis but indicated that the IL-12/Th1 signaling 
pathway elicits pathology. The disease was pre-
vented by IFN-γ deletion (Figure 4) [62, 65]. (iii) 
Th17 signaling suppressed the accumulation of 
IFN-γ-producing cells in the liver during the early 
phase of cholangitis [62], supporting the hypothe-
sis that IFN-γ is a key factor in the induction of bil-
iary autoimmunity. Thus, we emphasize that the 
pathology of PBC is mediated through IFN-γ-relat-
ed pathways. For example, one may postulate that 
Figure 2. Structures of lipoic acid and 2OA-BSA. 
2OA is conjugated with BSSA and used for immu-
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Figure 3. Detection and quantification of anti- 
PDC-E2 antibody in sera of 2-OA-BSA-immunized 
mice by using enzyme-linked immunosorbent as-
say at 2-week intervals after immunization. Signifi-
cant increase in optical density (OD) were observed 
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Figure 4. IFN-γ knockout completely abolished autoimmune cholangitis. Portal inflammatory changes with inter-
lobular bile duct damage (red arrow) were observed in wild-type mice (B6 mice) and normal bile ducts in IFN-γ–/– 
mice (blue arrows) [62]
B6 IFN-γ–/–
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after a liver environmental insult, local up regula-
tion of IFN-γ in a genetically susceptible host will 
lead to loss of tolerance. These events may occur 
serially, each leading to an up regulation of MHC 
in target tissue, further contributing to an auto-
immune response. We should note that activation 
of naive CD4 T cells from healthy women produc-
es higher levels of IFN-γ and lower levels of IL-17 
than those from healthy men [66]. Increased IFN-γ 
levels have also been demonstrated in patients 
with autoimmune diseases [34, 67]. However, 
no optimal model has been developed to deter-
mine how IFN-γ and gender together could elicit 
female-biased cholangitis in patients with PBC. 
In particular, whether IFN-γ is the first trigger in 
breaking tolerance needs to be addressed.
An ARE Del–/– mice as a novel PBC model
To solve this problem, we took advantage of 
a  “designer” mouse with dysregulation of IFN-γ, 
in which adenylate uridine-rich element (ARE) of 
the IFN-γ 3'-untranslated region was deleted [68]. 
In these mice, regulation of IFN-γ is disrupted and 
is constantly produced.
The ARE Del–/– mice have mild autoimmune 
manifestations similar to lupus early in life. Adult 
mice reflect many symptoms similar to human 
PBC, including liver histology, AMA production, 
and elevation of serum total bile acid (TBA) levels 
[69]. Furthermore, these features are predomi-
nantly found in female mice. In male ARE Del–/– 
mice, portal inflammation was scarcely found, 
and serum titers of AMA were elevated but not 
significantly in comparison with those in wild-
type mice (Figure 5). The TBA levels were com-
parable. Furthermore, gene expression analysis 
revealed that upregulated genes in female ARE 
Del–/– mice specifically overlapped with the gene 
expression signature of BECs in human PBC. 
Therefore, female ARE Del–/– mice mimic human 
PBC closely, making ARE Del–/– mice an ideal PBC 
mouse model.
Female predominance occurs in ARE Del–/– mice 
probably because female hormones and genet-
ics shape the immune system in female mice to 
generate more IFN-γ-producing cells. On the other 
hand, male mice may be protected by androgens, 
which favor up regulation of regulatory cells and 
down regulation of IFN-γ-producing cells. Female 
hormones activate the T lymphocytes to express 
more IFN-γ in female mice in this mouse model. 
Although many spontaneous and induced murine 
models have been reported as PBC mouse models 
[65], no single model has exhibited female domi-
nance as observed in this ARE Del –/– mice.
IFN-γ may play a pathogenic role in BECs in the 
initiation stage of PBC, and alteration of expres-
sion levels of IFN-γ would be critical for the de-
velopment of PBC in susceptible individuals. Fur-
thermore, we demonstrated that transfer of CD4 
T cells from ARE Del–/– mice to B6/Rag1–/– mice 
(an immune-deficient strain lacking mature T or 
B cells) induced moderate portal and parenchymal 
inflammations, implying that CD4+ T cells mainly 
contribute to the induction of cholangitis [69].
What then are the therapeutic targets in PBC?
Although the pathogenesis of PBC is still not 
fully understood, progression of the disease from 
early to late stage is divided into 3 steps: (i) loss of 
tolerance against PDC-E2, which leads to inflam-
mation and bile duct damage; (ii) insults to BECs 
with toxic bile acids due to chronic cholestasis; 
and (iii) liver fibrosis. Thus, treatment targets are 
mainly considered as inhibition of autoimmunity 
or modification of lymphocytes targeted to the 
liver, detoxification of harmful bile acids, and re-
versal of the fibrotic process [31]. As anti-fibrotic 
drugs are expected to be effective for all liver dis-
eases regardless of etiologies, we will focus on the 
modification of autoimmunity and detoxification 
of harmful bile acids (Table II).
PBC is an autoimmune-mediated liver disease, 
and homing of autoantigen specific T lymphocytes 
Figure 5. AMA levels in ARE-Del–/– female (A) and male (B) mice at 20 weeks [69]
WT – wild type.
 PDC-E2 OGDC-E2 BCOADC-E2
 WT          ARE
 PDC-E2 OGDC-E2 BCOADC-E2
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to the liver plays a crucial role in its pathogenesis. 
However, clinical trials with immunosuppressive 
agents have essentially failed, including corticoste-
roids, methotrexate, azathioprine budenoside and 
select biologics. Among these trials, B-cell depletion 
with anti-CD20 had been expected to be effective 
in PBC [57]. Although non-specific inhibition of ac-
tivation of T cells was thought to be a candidate for 
therapeutic trials, overall results from clinical trials 
with anti-CD40, chimeric CTLA4 (abatacept), and an-
ti-IL12/IL23 (ustekinumab) were disappointing [70].
Biliary epithelial cells damaged by innate and/
or acquired immunity impede smooth flow of 
bile within the bile ducts, which leads to chronic 
cholestasis. In normal conditions, the “bicarbon-
ate umbrella”, a  layer of secreted bicarbonate 
onto biliary epithelial cells, protects them from 
toxic bile acids. Impairment of this umbrella con-
tributes to development of cholestasis in PBC [71]. 
Hydrophobic bile acids such as lithocholic acid 
are highly toxic to biliary epithelial cells and he-
patocytes. Therefore, reducing the toxicity of hy-
drophobic bile acids through decreasing bile acid 
synthesis and stimulating choleresis would be 
another possible regimen in cholestatic liver dis-
eases such as PBC [72]. So far, many compounds 
have been developed for detoxification of hydro-
phobic bile acids, and mechanisms of these drugs 
are largely classified into three categories: reduc-
tion of intrahepatic de novo synthesis of bile ac-
ids, choleresis through modification of hepatic bile 
acid transporters, and blocking bile acid transport-
ers at the ileum for disturbing the reabsorption of 
bile acids [73].
Modification of autoimmunity
Rituximab that leads to B-cell depletion and 
ant-fractalkine antibody were expected to be ef-
fective and clinical trials are in preparation. Rit-
uximab is anti-CD20 antibody, clinically used for 
several indications associated with B lymphocytes 
such as non-Hodgkin lymphoma. B-cell depletion 
with anti-CD20 antibody ameliorates cholangitis 
in dnTGF-bRII mice, but preliminary data in clin-
ical trials suggested conflicting results [74, 75]. 
Recently, several novel anti-CD20 antibodies have 
been developed and approved for B-cell lympho-
ma [76] and are expected to be investigated in 
patients with PBC as well.
Pathogenic T lymphocytes are activated and 
recruited into the vicinity of the bile ducts from 
the portal vein. During this homing process of 
T lymphocytes, chemokines play an important 
role. Previous studies demonstrated that CX3CL1 
(a  chemokine called fractalkine) production was 
augmented with TLR3 by biliary epithelial cells in 
PBC, and CX3CR1 (the receptor of fractalkine)-pos-
itive lymphocytes invade into biliary tract by en-
gaging CX3CL1, thereby causing cholangitis [77]. 
Anti-fractalkine antibody (E6011), originally devel-
oped for rheumatoid arthritis [78] and Crohn’s dis-
ease, is thus expected to be effective for PBC, and 
the phase 2 trial of E6011 for PBC with incomplete 
response to UDCA will be soon launched in 2017.
Obeticholic acid
Alternative treatment options for PBC patients 
refractory to UDCA have been long awaited. In 
2016, the Food and Drug Administration (FDA) of-
ficially approved OCA, based on the results of the 
phase 3 clinical trial of OCA (POISE trial) [10]. OCA is 
a selective ligand of the farnesoid X receptor (FXR). 
Bile acid toxicity against biliary epithelial cells and 
hepatocytes is decreased by FXR signaling through 
impairment of bile acid synthesis and stimulation 
of choleresis. The endogenous FXR ligand is cheno-
deoxycholic acid (CDCA), a primary bile acid. Com-
pared with CDCA, OCA is approximately 100 times 
more potent than CDCA in activating FXR [79].
In the POISE trial, 217 patients with PBC who 
showed an inadequate response (serum alkaline 
phosphatase (ALP) level of > 1.67 × ULN) or an ab-
normal total bilirubin level (< 2 times × ULN), or 
intolerance to UDCA were enrolled and received 
5–10 mg of OCA, 10 mg of OCA, and placebo for 
1 year. The primary end point was ALP level of 
< 1.67 × ULN with > 15% reduction from the base-
line and normal bilirubin level. Of the patients, 
Table II. Pathogenic and therapeutic targets of PBC
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46–47% of patients achieved the primary end 
point [10]. Consequently, OCA received accelerat-
ed FDA approval on May 27, 2016.
While OCA has become the second-line drug 
officially approved for PBC and is well accepted, 
it remains suboptimal for several reasons: First, 
the response rate was at most 50%, which means 
that half of the patients did not respond to OCA. 
Second, pruritus, a  frequent symptom of PBC, 
appeared as an adverse effect in 56–68% of pa-
tients treated with OCA. Furthermore, whether 
the primary end points (ALP level < 1.67 × ULN 
with > 15% reduction from the baseline and nor-
mal bilirubin level) are associated with improve-
ment of long-term outcomes has not been con-
firmed yet [80]. In this regard, follow-up studies 
of the POISE trial were required by the FDA, and 
a  phase 3 study is currently ongoing (COBALT, 
NCT02308111). Finally, OCA treatment should be 
continued for patients refractory to UDCA; thus, 
OCA may be prescribed lifelong along with UDCA. 
Based on the high cost of OCA ($69,350 per year), 
this unlimited prescription of OCA may cause sub-
stantial economic burden on both patients and 
society, Samur et al. recently demonstrated that 
the price should be decreased to $18,450 per year 
to make OCA cost-effective [81].
Fibrates
Fibrates (fenofibrate and bezafibrate) were 
originally labeled for dyslipidemia and used for 
decreasing serum cholesterol and triglycerides. 
Fibrates are PPAR-alfa and PXR agonists, result-
ing in reduction of de novo bile acid synthesis 
and up regulation of bile acid transporters [82]. 
Bezafibrate was first reported as biologically ef-
fective for PBC patients refractory to UDCA in 
1999 [83]; since then, it has been used as an 
off-label second-line drug in Japan. A large-scale 
retrospective cohort study in Japan demonstrat-
ed that patients with good response to bezafi-
brate (normalization of ALT) exhibited a  com-
parable prognosis to those treated with UDCA 
alone and significantly better outcomes than 
those with poor response to bezafibrate [84]. Re-
cently, a prospective randomized study in Japan 
revealed that long-term outcomes were not sig-
nificantly different between the UDCA plus be-
zafibrate and UDCA only groups, but the sample 
size in this study might be too small to establish 
enough statistical power [85]. Another prospec-
tive, randomized phase 3 study of bezafibrate 
for patients with PBC with incomplete responses 
to UDCA is ongoing in France (NCT01654731). 
Fenofibrate was reported to decrease serum 
ALP levels in studies in Japan and China [86, 87], 
while adjunct use of fenofibrate to UDCA showed 
no association with decreased serum ALP levels 
in a UK cohort [88]. Participants are being recruit-
ed for a prospective randomized study in China 
(NCT02965911). However, these two prospective 
clinical trials showed improved liver enzyme lev-
els notably at 12 or 24 months as the primary 
end point. Even after these trials are terminat-
ed, whether long-term outcomes are improved 
with additional treatment with fibrates is still 
unknown, and follow-up studies of these trials 
are needed.
Ileal bile acid transporter inhibitors
Bile acids are essential to the human body, and 
98% of bile acids excreted into the intestine are 
reabsorbed from the ileum bile acid transporter 
(IBAT) and returned to the liver via portal tract, 
known as enterohepatic circulation. In cholestatic 
liver disease, ileal bile acid absorption is increased 
[89]. Therefore, another strategy for reducing bile 
acids is blocking IBAT. One of these compounds, 
GSK2330672, did not significantly decrease serum 
ALP levels in patients with incomplete responses 
to UDCA but was demonstrated to significantly 
improve pruritus in comparison with placebo [90]. 
A  prospective, randomized, placebo-controlled 
phase 2 study of GSK2330672 is launched in 2017 
(NCT02966834).
Future direction with the ARE Del–/– mouse 
model
Although PBC is clearly a  heterogeneous dis-
ease, the therapeutic approach is similar for all 
patients and not satisfactory at all even with OCA. 
This is partly due to the lack of animal models that 
could be used for investigating the immunopathol-
ogy of PBC and the efficacy of newly developed 
compounds. In this regard, ARE Del–/– mice, which 
closely mimic human PBC, is currently the most 
attractive model. ARE Del–/– mice provides the fol-
lowing benefits. First, this is a female-predominant 
model for PBC, which allows for investigation on 
mechanisms of female predominance in the dis-
ease. We can conduct a comprehensive analysis on 
sexual dimorphic physiological systems, including 
hormones, immune differences, and microbiome. 
We can alter estrogen and estrogen receptors on 
cells to study their effect on disease process and 
pathology. We can also examine the female micro-
biome to resemble the male microbiome and raise 
these mice in a germ-free environment for further 
systematic introduction of selected bacteria. Sec-
ond, this model will aid in determining which gene 
pathways may help or hinder the progress of PBC 
in both sexes. Third, this model also enables us 
to examine over time the interaction of multiple 
cellular messengers and their role in the develop-
ment of autoimmune state. Finally, this model has 
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vast implications for clinical research. It allows for 
examination of the heterogeneity and the natural 
history of PBC, from the early, asymptomatic stage 
to the late stage and the possibility to discover 
new biomarkers along different stages. This mouse 
also provides an effective tool for assessing the ef-
fect of drugs currently used or under development, 
and for designing novel, more-effective drugs for 
the clinical management of PBC.
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